Immunomodulator with antiviral effect :: Consumers survey results of for 2 quarter of 2008

Consumers survey results of for 2 quarter of 2008 in category

Antiviral medications / Immunomodulator with antiviral effect

The annual ratings by results of Consumers survey calculated as average arithmetic mean rank, obtained in each of 4 quarters of year.

	I quarter (january—march)
	II quarter (april—june)
	III quarter (july—september)
	IV quarter (october—december)

1.		IRS 19 (Abbott Laboratories)	35.71%	5

2.	3	Імунал (Sandoz)	28.57%	4

2.		Ехінацея-ратіофарм (ratiopharm)	28.57%	4

4.	2	Imudon (Abbott Laboratories)	17.86%	2.50

5.	2	Amizon (Farmak)	14.29%	2

6.	3	Ехінацея Гексал (Sandoz)	10.71%	1.50

7.	~	Аміксин IC (InterChem)	7.14%	1

7.	~	Вобензим (Mucos Pharma)	7.14%	1

7.	~	Ехінацин (Madaus)	7.14%	1

7.	4	Оригінальний Великий Бальзам Біттнеру (Perrigo)	7.14%	1

11.	~	Імумод (Wockhardt)	3.57%	0.50

11.	4	Імуновіт (GlaxoSmithKline)	3.57%	0.50

11.	~	Імуноплюс (Київський вітамінний завод)	3.57%	0.50

11.	4	Гербіон Ехінацея (KRKA)	3.57%	0.50

–.		Derinat drops (Technomedservice)	0.00%	0

–.		Імуно Тайсс (Naturprodukt Vega (Dr. Theiss Naturwaren GmbH))	0.00%	0

–.		Імуно-тон (Arterium Corporation)	0.00%	0

–.		Імуногран-Здоров’я (Pharmaceutical company “Zdorovya”)	0.00%	0

–.		Галавіт (Медікор, Москва)	0.00%	0

–.		Назоферон (Farmak)	0.00%	0

Using this rating is only possible with obligatory link to the source.

This rating was built as a result of the study of social preferences in 2008, under the “Favorites of Success” Contest in Ukraine and it’s the free information. In case of full or partial republishing of the information drawn from this rating, it is obligatory to mention the name of the “Favorites of Success” Contest in printed publications, or put an active hyperlink to this page in the electronic media.

Advanced reporting booklet about the study, including demographics of the respondents, by regional breakdown, information roll-call of ad hoc judges etc, can also be obtained from managers of the contest.